Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccinations01:51

Vaccinations

50.9K
Overview
50.9K
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

150
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
150
Healthcare Associated Infections II: Preventive Measures01:22

Healthcare Associated Infections II: Preventive Measures

3.5K
Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
3.5K
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

643
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
643
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

134
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
134
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

194
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
194

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Budget impact analysis of Haemate-<i>P</i> as long-term prophylaxis and on-demand therapy for von Willebrand disease in Spain.

Journal of medical economics·2025
Same author

Cost-effectiveness and cost-utility analysis of Haemate-P versus other von Willebrand disease treatments in Spain.

Journal of medical economics·2025
Same author

Cost-effectiveness of Voncento prophylaxis vs on-demand treatment in von Willebrand disease in the United Kingdom.

Blood advances·2024
Same author

The Health and Economic Effects of PCV15 and PCV20 During the First Year of Life in the US.

Vaccines·2024
Same author

Analysis of long-term clinical and cost impact of etranacogene dezaparvovec for the treatment of hemophilia B population in the United States.

Journal of medical economics·2024
Same author

Assessing health plan payer's budget impact of etranacogene dezaparvovec for the treatment of hemophilia B in the United States.

Journal of managed care & specialty pharmacy·2024

Related Experiment Video

Updated: Dec 24, 2025

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

15.5K

Health and Economic Impact of Routine Pediatric Pneumococcal Immunization Programs in Canada: A Retrospective

Michele R Wilson1, Matthew D Wasserman2, Marie-Claude Breton3

  • 1RTI Health Solutions, Research Triangle Park, NC, USA.

Infectious Diseases and Therapy
|April 10, 2020
PubMed
Summary

Pneumococcal conjugate vaccine (PCV) programs in Canada saved over 6,600 lives and averted millions of disease cases between 2005-2015. These vaccination programs provided significant health benefits and economic value, saving CAD $1.76 billion.

Keywords:
Acute otitis mediaChildren vaccinationPneumococcal diseasePneumococcal vaccinationPneumoniaPublic health impact

More Related Videos

Experimental Human Pneumococcal Carriage
07:47

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

16.1K
Using the Overlay Assay to Qualitatively Measure Bacterial Production of and Sensitivity to Pneumococcal Bacteriocins
06:05

Using the Overlay Assay to Qualitatively Measure Bacterial Production of and Sensitivity to Pneumococcal Bacteriocins

Published on: September 30, 2014

14.0K

Related Experiment Videos

Last Updated: Dec 24, 2025

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

15.5K
Experimental Human Pneumococcal Carriage
07:47

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

16.1K
Using the Overlay Assay to Qualitatively Measure Bacterial Production of and Sensitivity to Pneumococcal Bacteriocins
06:05

Using the Overlay Assay to Qualitatively Measure Bacterial Production of and Sensitivity to Pneumococcal Bacteriocins

Published on: September 30, 2014

14.0K

Area of Science:

  • Public Health
  • Epidemiology
  • Health Economics

Background:

  • Pneumococcal conjugate vaccines (PCV) have been implemented in Canada.
  • Estimating the comprehensive impact of PCV programs is crucial for public health policy.

Purpose of the Study:

  • To model the historical health and economic impact of Canadian PCV programs from 2005 to 2015.
  • To quantify the total societal benefit of PCV implementation.

Main Methods:

  • Developed a model to estimate disease cases averted by PCV.
  • Compared observed incidence (2005-2015) with a hypothetical scenario of no PCV use.
  • Utilized epidemiologic data for invasive pneumococcal disease (IPD), pneumonia, and acute otitis media (AOM).

Main Results:

  • PCV programs averted 14,990 IPD cases, 735,700 pneumonia episodes, and 3,697,993 AOM episodes.
  • An estimated 6,631 lives were saved.
  • Total cost savings reached CAD $1.76 billion over 11 years, with vaccination costs offset by reduced medical expenditures.

Conclusions:

  • Canadian PCV programs demonstrate substantial health benefits and excellent value for money.
  • Net savings can fund other critical health care initiatives.
  • The total value of vaccination programs, beyond acquisition costs, should guide policy decisions.